GlassScriptPhysician profile
Millard J Collier Jr
NPI 1306860044
$49,872.96
in general payments reported to CMS, 2019-2025
48 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $15K · 2021: $2,782 · 2022: $2,098 · 2023: $7,015 · 2024: $4,052 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,854 · Travel and Lodging: $2,507 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,343 · Consulting Fee: $2,325 · Debt Forgiveness: $671 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,854.35 |
| Travel and Lodging | $2,507.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,342.50 |
| Consulting Fee | $2,325.00 |
| Debt Forgiveness | $670.72 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18,835.10 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,098.75 | 2019-2025 | Jardiance |
| Pfizer INC. | $4,993.64 | 2019-2024 | |
| Ucb, INC. | $2,439.34 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,151.03 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,991.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,420.72 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lifenet Health | $1,047.62 | 2025 | Theragenesis Wound Matrix |
| Amarin Pharma, INC. | $899.18 | 2019-2023 | |
| Optos, INC. | $670.72 | 2023 | Nfc-700 |
| Bayer Healthcare Pharmaceuticals INC. | $665.37 | 2021-2025 | |
| Exact Sciences Corporation | $608.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $418.62 | 2019-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $407.23 | 2021-2024 | Livalo, Seglentis, Zoryve |
| Dexcom, INC. | $325.86 | 2021-2023 | Dexcom G6 Transmitter |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $305.40 | 2021-2023 | Hetlioz |
| Abbvie INC. | $290.42 | 2021-2024 | Vraylar |
| Eisai INC. | $281.98 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $204.01 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $191.93 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Idorsia Pharmaceuticals US INC | $181.41 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $156.42 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $123.50 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $123.06 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $119.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $87.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $77.81 | 2019-2023 | Belsomra, Steglatro |
| Arbor Pharmaceuticals, INC. | $76.52 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $64.25 | 2022 | |
| Allergan, INC. | $64.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.12 | 2019-2023 | Xifaxan |
| Zimmer Biomet Holdings, INC. | $61.31 | 2023 | Stratum Foot Plating System |
| Esperion Therapeutics, INC. | $60.87 | 2021-2022 | |
| Kyowa Kirin, INC. | $44.61 | 2024-2025 | Crysvita |
| Horizon Therapeutics Plc | $42.75 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.64 | 2022-2024 | Caplyta |
| Merz North America, INC. | $40.37 | 2023 | |
| Sumitomo Pharma America, INC. | $39.61 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $27.67 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $20.45 | 2022 | |
| Medline Industries LP | $16.94 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.41 | 2022 | |
| Travere Therapeutics, INC. | $15.37 | 2023 | Cholbam |
| Phathom Pharmaceuticals, INC. | $14.41 | 2024 | Voquezna |
| Atland Pharmaceuticals, LLC | $13.60 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Almatica Pharma LLC | $12.67 | 2022 | |
| Gilead Sciences, INC. | $12.42 | 2020 | |
| Linus Health, INC. | $8.69 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millard Collier Jr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.